Impact of an Altered Wnt1/β-Catenin Expression on Clinicopathology and Prognosis in Clear Cell Renal Cell Carcinoma
Open accessThe DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
In renal cell carcinoma (RCC), single members of the Wnt/β-catenin signaling cascade were recently identified to contribute to cancer progression. However, the role of Wnt1, one of the key ligands in β-catenin regulation, is currently unknown in RCC. Therefore, alterations of the Wnt1/β-catenin axis in clear cell RCC (ccRCC) were examined with regard to clinicopathology, overall survival (OS) and cancer specific survival (CSS). Corresponding ccRCCs and benign renal tissue were analyzed in 278 patients for Wnt1 and β-catenin expression by immunohistochemistry in tissue microarrays. Expression scores, including intensity and percentage of stained cells, were compared between normal kidney and ccRCCs. Data was categorized according to mean expression scores and correlated to tumor and patients’ characteristics. Survival was analyzed according to the Kaplan-Meier and log-rank test. Univariable and multivariable Cox proportional hazard regression models were used to explore the independent prognostic value of Wnt1 and β-catenin. In ccRCCs, high Wnt1 was associated with increased tumor diameter, stage and vascular invasion (p ≤ 0.02). High membranous β-catenin was associated with advanced stage, vascular invasion and tumor necrosis (p ≤ 0.01). Higher diameter, stage, node involvement, grade, vascular invasion and sarcomatoid differentiation (p ≤ 0.01) were found in patients with high cytoplasmic β-catenin. Patients with a high cytoplasmic β-catenin had a significantly reduced OS (hazard ratio (HR) 1.75) and CSS (HR 2.26), which was not independently associated with OS and CSS after adjustment in the multivariable model. Increased ccRCC aggressiveness was reflected by an altered Wnt1/β-catenin signaling. Cytoplasmic β-catenin was identified as the most promising candidate associated with unfavorable clinicopathology and impaired survival. Nevertheless, the shift of membranous β-catenin to the cytoplasm with a subsequently increased nuclear expression, as shown for other malignancies, could not be demonstrated to be present in ccRCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As c-Myc and Cyclin D1 are key drivers of cell proliferation, this directly links the PPP1R18/ERK/Wnt/β-catenin axis to the proliferative phenotype of ccRCC [56–58].”
From PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma (2026) · cites this paper as [56]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Wnt/β-Catenin Signaling in Development and Disease
Clevers, H. (2006) · Cell · doi:10.1016/j.cell.2006.10.018 · Cited by 5,568 · cited 2×
“Here, elevated transcription of LEF/TCF-responsive target genes, such as c-myc or cyclin D1, promote deregulated cell differentiation and apoptosis [10,12].”
Nusse, R., & Varmus, H. E. (1982) · Cell · doi:10.1016/0092-8674(82)90409-3 · Cited by 1,863 · cited 1×
“The first discovered Wnt1 protein was identified as a virus-induced proto-oncogene in mouse mammary tumors in 1982 [20].”
BackgroundThe many faces and functions of β‐catenin
Valenta, T., Hausmann, G., & Basler, K. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.150 · Cited by 1,598
Secreted antagonists of the Wnt signalling pathway
Kawano, Y., & Kypta, R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00623 · Cited by 1,584 · cited 1×
“Second, the loss of function of Wnt antagonist has been frequently reported to be associated with Wnt/β-catenin signal activation and RCC development [30–34].”
BackgroundInoki, K., Ouyang, H., Zhu, T., Lindvall, C., Wang, Y., Zhang, X., Yang, Q., Bennett, C., Harada, Y., Stankunas, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.06.055 · Cited by 1,377
Satoh, S., Daigo, Y., Furukawa, Y., Kato, T., Miwa, N., Nishiwaki, T., Kawasoe, T., Ishiguro, H., Fujita, M., Tokino, T., et al. (2000) · Nature Genetics · doi:10.1038/73448 · Cited by 960 · cited 1×
“These mechanisms are particularly evident in colorectal and hepatocellular carcinomas, where frequent associations with gene mutations of the β-catenin regulator genes, adenomatous polyposis coli (APC) or AXIN, are found [13].”
BackgroundInterplay of Cadherin-Mediated Cell Adhesion and Canonical Wnt Signaling
Heuberger, J., & Birchmeier, W. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a002915 · Cited by 619 · cited 1×
“In addition, canonical Wnt/β-catenin signaling affects EMT by cadherin-mediated cell adhesion, which controls the expression of adhesion enzymes, mesenchymal genes and directly affects cell motility [26].”
BackgroundWNT-1 Signaling Inhibits Apoptosis by Activating β-Catenin/T Cell Factor–Mediated Transcription
Chen, S., Guttridge, D. C., You, Z., Zhang, Z., Fribley, A., Mayo, M. W., Kitajewski, J., & Wang, C.-Y. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.152.1.87 · Cited by 394
Gumz, M. L., Zou, H., Kreinest, P. A., Childs, A. C., Belmonte, L. S., LeGrand, S. N., Wu, K. J., Luxon, B. A., Sinha, M., Parker, A. S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0143 · Cited by 297 · cited 1×
“In particular, the loss of secreted-Frizzled related proteins (sFRP) leads to increased cytoplasmic β-catenin levels in RCC experiments [33,34].”
Background
Cited by
Wnt/beta-catenin pathway: modulating anticancer immune response
Pai, S. G., Carneiro, B. A., Mota, J. M., Costa, R., Leite, C. A., Barroso-Sousa, R., Kaplan, J. B., Chae, Y. K., & Giles, F. J. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0471-6 · Cited by 703
Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy
Song, P., Gao, Z., Bao, Y., Chen, L., Huang, Y., Liu, Y., Dong, Q., & Wei, X. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01563-4 · Cited by 382
“Some of these aberrations include upregulation of Wnt1 [249] and Wnt10a [250], as well as downregulation of Wnt5a [251] and Wnt7a [252].”
BackgroundInhibiting WNT and NOTCH in renal cancer stem cells and the implications for human patients
Fendler, A., Bauer, D., Busch, J., Jung, K., Wulf-Goldenberg, A., Kunz, S., Song, K., Myszczyszyn, A., Elezkurtaj, S., Erguen, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14700-7 · Cited by 189
Wnt Signaling in Kidney Development and Disease
Wang, Y., Zhou, C. J., & Liu, Y. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.11.019 · Cited by 158
The epigenetic landscape of renal cancer
Morris, M. R., & Latif, F. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.168 · Cited by 147
Wnt Signaling in Renal Cell Carcinoma
Xu, Q., Krause, M., Samoylenko, A., & Vainio, S. (2016) · Cancers · doi:10.3390/cancers8060057 · Cited by 99
Kerdidani, D., Chouvardas, P., Rocañín-Arjó, A., Giopanou, I., Ntaliarda, G., Guo, Y. A., Tsikitis, M., Kazamias, G. M., Potaris, Κ., Stathopoulos, G. T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09370-z · Cited by 104
DNA Methyltransferase Inhibitors: Catalysts For Antitumour Immune Responses
Dan, H., Zhang, S., Zhou, Y., & Guan, Q. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s217767 · Cited by 86
Wang, Q., Xu, J., Xiong, Z., Xu, T., Liu, J., Liu, Y., Chen, J., Shi, J., Shou, Y., Yue, C., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03087-8 · Cited by 89
Zhang, L., Zha, Z., Qu, W., Zhao, H., Yuan, J., Feng, Y., & Wu, B. Y. (2018) · BMC Cancer · doi:10.1186/s12885-018-4773-z · Cited by 77
Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
Zerbini, L. F., Bhasin, M., de Vasconcellos, J. F., Paccez, J. D., Gu, X., Kung, A. L., & Libermann, T. A. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0750 · Cited by 70
“High WNT1 expression correlates with increased tumor diameter, stage and vascular invasion (30).”
BackgroundLu, J., Wei, J.-H., Feng, Z.-H., Chen, Z.-H., Wang, Y.-Q., Huang, Y., Fang, Y., Liang, Y.-P., Cen, J.-J., Pan, Y.-H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15591 · Cited by 51
Kimura, R., Kasamatsu, A., Koyama, T., Fukumoto, C., Kouzu, Y., Higo, M., Endo‐Sakamoto, Y., Ogawara, K., Shiiba, M., Tanzawa, H., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-555 · Cited by 57
“β-catenin plays crucial and diverse roles in cadherinmediated cell-cell adhesion, Wnt signal transduction, gene activation, and tumoral formation [39-41].”
BackgroundGe, Y., Wang, C., Hu, F., Pan, L., Min, J., Niu, K., Zhang, L., Li, J., & Xu, T. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25853 · Cited by 49
Renal cancer: signaling pathways and advances in targeted therapies
Jiang, A., Li, J., He, Z., Liu, Y., Qiao, K., Fang, Y., Qu, L., Luo, P., Lin, A., & Wang, L. (2024) · MedComm · doi:10.1002/mco2.676 · Cited by 51
“70,71 Conversely, noncanonical ligands, including Wnt7A and Wnt5A , are downregulated, 72,73 and their reduced expression may also be implicated in the development of renal cancer.”
BackgroundZhang, X., Yang, M., Shi, H., Hu, J., Wang, Y., Sun, Z., & Xu, S. (2017) · Oncotarget · doi:10.18632/oncotarget.15361 · Cited by 54
Expression of Wnt-5a and β-catenin in primary hepatocellular carcinoma.
Li, P., Cao, Y., Li, Y., Zhou, L., Liu, X., & Geng, M. (2014) · PubMed Central · Cited by 42
miR-124 represses FZD5 to attenuate P-glycoprotein-mediated chemo-resistance in renal cell carcinoma
Long, Q., Du, Y., Liu, X., Li, X., & He, D. (2015) · Tumor Biology · doi:10.1007/s13277-015-3369-3 · Cited by 41
Role of β-Catenin Activation Levels and Fluctuations in Controlling Cell Fate
Pedone, E., & Marucci, L. (2019) · Genes · doi:10.3390/genes10020176 · Cited by 45
Chen, Y., Huang, Q., Zhou, H., Wang, Y., Hu, X. M., & Li, T. (2016) · Oncotarget · doi:10.18632/oncotarget.10409 · Cited by 37
Li, J., Wu, G., Xu, Y., Li, J., Ruan, N., Chen, Y., Zhang, Q., & Xia, Q. (2020) · BioMed Research International · doi:10.1155/2020/2527643 · Cited by 41
Górka, J., Marona, P., Kwapisz, O., Waligórska, A., Pośpiech, E., Dobrucki, J. W., Ryś, J., Jura, J., & Miękus, K. (2021) · Oncogene · doi:10.1038/s41388-021-02062-3 · Cited by 37
Huang, J., Liao, Y., Qiu, M., Li, J., & An, Y. (2017) · Tumor Biology · doi:10.1177/1010428317711314 · Cited by 35
Zhang, L., Wu, B. Y., Zha, Z., Zhao, H., & Feng, Y. (2018) · Cancer Management and Research · doi:10.2147/cmar.s166710 · Cited by 29
Dzobo, K., Thomford, N. E., & Senthebane, D. A. (2019) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2019.0147 · Cited by 33
“Upregulated levels of b -catenin are reportedly associated with poor prognosis in renal cell carcinoma (Kruck et al., 2013).”
Prognostic significance of GAD1 overexpression in patients with resected lung adenocarcinoma
Tsuboi, M., Kondo, K., Masuda, K., Tange, S., Kajiura, K., Kohmoto, T., Takizawa, H., Imoto, I., & Tangoku, A. (2019) · Cancer Medicine · doi:10.1002/cam4.2345 · Cited by 26
Cimadamore, A., Gasparrini, S., Santoni, M., Liang Cheng, C., Antonio Lopez-beltran, B., Battelli, N., Massari, F., Giunchi, F., Fiorentino, M., Scarpelli, M., et al. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1490179 · Cited by 25
Kim, N. Y., Jung, Y. Y., Yang, M. H., Chinnathambi, A., Govindasamy, C., Narula, A. S., Namjoshi, O. A., Blough, B. E., & Ahn, K. S. (2022) · Biochimie · doi:10.1016/j.biochi.2022.05.018 · Cited by 24
Lee, Y., Chao, T., Sheu, M., Tian, Y., Chen, T., Lee, S., He, H.-L., Chang, I., Hsing, C., Lin, C., et al. (2016) · Journal of Cancer · doi:10.7150/jca.15667 · Cited by 24
Wong, D. W. L., Yiu, W. H., Wu, H., Li, R. X., Liu, Y., Chan, K. W., Leung, J. C. K., Chan, L. Y. Y., Lai, K. N., & Tang, S. C. W. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.62 · Cited by 23
Krabbe, L., Westerman, M. E., Bagrodia, A., Gayed, B. A., Darwish, O. M., Haddad, A., Khalil, D., Kapur, P., Sagalowsky, A. I., Lotan, Y., et al. (2013) · The Journal of Urology · doi:10.1016/j.juro.2013.11.052 · Cited by 22
Hu, C., Zhao, Y., Wang, X., & Zhu, T. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.651620 · Cited by 21
Zi, X., Lusch, A., Blair, C. A., Okhunov, Z., Yokoyama, N. N., Liu, S., Baker, M., Huynh, V. B., & Landman, J. (2016) · Oncotarget · doi:10.18632/oncotarget.10467 · Cited by 20
Dong, J., Li, Y., & Shi, K. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0743-z · Cited by 20
Piotrowska, Ż., Niezgoda, M., Młynarczyk, G., Acewicz, M., & Kasacka, I. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.566637 · Cited by 25
Clinical and Molecular Prognostic and Predictive Biomarkers in Clear Cell Renal Cell Cancer
Czarnecka, A. M., Kukwa, W., Kornakiewicz, A., Lian, F., & Szczylik, C. A. (2014) · Future Oncology · doi:10.2217/fon.14.162 · Cited by 18
New insights into fibrotic signaling in renal cell carcinoma
Chen, J., Yiu, W. H., Tang, P. M., & Tang, S. C. W. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1056964 · Cited by 19
HIF2α Promotes Cancer Metastasis through TCF7L2-Dependent Fatty Acid Synthesis in ccRCC
Shi, J., Lv, Q., Miao, D., Xiong, Z., Wei, Z., Wu, S., Tan, D., Wang, K., & Zhang, X. (2024) · Research · doi:10.34133/research.0322 · Cited by 29
Cui, L., Zhao, J., & Liu, J. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2017.11.017 · Cited by 17
Fan, W., Huang, J., & Xiao, H. (2015) · Europe PMC (PubMed Central) · Cited by 17
Xie, D., Li, J., Wei, S., Pan, Q., Ji, H., Su, J., Du, N., & Zhang, X. (2020) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2020.101608 · Cited by 14
Targeting Strategies for Renal Cancer Stem Cell Therapy
Fang, P., Zhou, L., Lim, L. Y., Fu, H., Yuan, Z., & Lin, J. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200318153106 · Cited by 13
Kovács, G., Billfeldt, N. K., Farkas, N., Dergez, T., Javorhazy, A., Bányai, D., Pusztai, C., & Szántó, Á. (2016) · Histopathology · doi:10.1111/his.13059 · Cited by 15
The Role of the PAX Genes in Renal Cell Carcinoma
Li, L., Hossain, S. M., & Eccles, M. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126730 · Cited by 11
“Multiple lines of evidence suggest the involvement of the Wnt/ β -catenin signaling pathway in RCC [122,123] (see Figure 3).”
BackgroundHuang, Z., Du, Y., Yin, H., Wang, G., & Xu, T. (2025) · Protein and Peptide Letters · doi:10.2174/0109298665357331250416081850 · Cited by 12
Durán, I., Castellano, D., Puente, J., Martín-Couce, L., Bello, E., Anido, U., Mas, J. M., & Costa, L. (2022) · Oncotarget · doi:10.18632/oncotarget.28183 · Cited by 11
DAB2IP modulates primary cilia formation associated with renal tumorigenesis
Lin, C., Dang, A., Hernández, E., & Hsieh, J. (2020) · Neoplasia · doi:10.1016/j.neo.2020.12.002 · Cited by 10
Antitumor Effect of Sclerostin against Osteosarcoma
Ideta, H., Yoshida, K., Okamoto, M., Sasaki, J., Kito, M., Aoki, K., Yoshimura, Y., Suzuki, S.-I., Tanaka, A., Takazawa, A., et al. (2021) · Cancers · doi:10.3390/cancers13236015 · Cited by 11
Wang, X., Xiao, Y., Li, S., Yan, Z., & Luo, G. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.647301 · Cited by 11
Comprehensive bioinformatic analysis of Wnt1 and Wnt1-associated diseases
Peng, C., Lu, Y., Ren, X., Wang, Y., Zhang, S., Chen, M., Liu, J., Fang, F., Li, T., & Han, J. (2020) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2020.01018 · Cited by 9
Han, B., Sun, Z., Yu, T., Wang, Y., Kuang, L., Li, T., Cai, J., Cao, Q., Xu, Y., Gao, B., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00484-2 · Cited by 9
Lu, X., & Jin, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1486783 · Cited by 11
Cernaro, V., Sfacteria, A., Rifici, C., Macrı̀, F., Maricchiolo, G., Lacquaniti, A., Ricciardi, C. A., Buemi, A., Costantino, G., Santoro, D., et al. (2016) · Journal of Nephrology · doi:10.1007/s40620-016-0353-y · Cited by 7
Xin, H., Tang, Y., Jin, Y.-H., Li, H., Yu, T., Cong, Y., Zhao, Z., Wu, M., & Pan, Y. F. (2023) · Cell Adhesion & Migration · doi:10.1080/19336918.2023.2260644 · Cited by 6
Zhong, K., Wang, X., Zhang, H., Chen, N., Mai, Y., Dai, S., Yang, L., Chen, D., & Zhong, W. (2024) · ACS Omega · doi:10.1021/acsomega.3c07265 · Cited by 11
Wirkmechanismen, neue Angriffspunkte und potentielle Biomarker bei moderner Immuntherapie
Bedke, J., Stühler, V., Todenhöfer, T., & Stenzl, A. (2018) · Der Urologe · doi:10.1007/s00120-018-0787-z · Cited by 6
Self-citationGórka, J., & Miękus, K. (2025) · Discover Oncology · doi:10.1007/s12672-025-02228-5 · Cited by 4
“A 2013 study involving the analysis of 278 samples from ccRCC patients and corresponding benign renal tissue revealed that high membrane-localized β-catenin content was associated with advanced tumor stage, vascular invasion, and necrosis (p ≤ 0.01) [23].”
InfluentialYan, C., Yang, Y. X., Tang, Y., Zheng, X., & Xu, B. (2022) · Journal of Oncology · doi:10.1155/2022/2909095 · Cited by 3
Sitaram, R. T., Ljungberg, B., Roos, G., Landström, M., & Sitaram, R. T. (2020) · Clinical Oncology and Research · doi:10.31487/j.cor.2020.03.09 · Cited by 2
Kundu, A., Sen, A., Choudhury, S., Mandal, T. K., Guha, D., & Lahiry, S. (2021) · Medicine and Pharmacy Reports · doi:10.15386/mpr-1767 · Cited by 2
Ji, X., Yun, Y., Zhu, Z., Wu, T., Ruan, M., Fan, Y., & Zhang, Q. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.112259 · Cited by 2
Lu, L., Jin, J., Lu, D., Peng, Y., & Fan, Y. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01966-8 · Cited by 1
“In ccRCC, elevated levels of Wnt1 expression have been shown to correlate with increased tumour size, advanced stage and vascular infiltration in patients [66 ].”
Novel Targets in Development for Advanced Renal Cell Carcinoma
Thapa, B., Nelson, A. A., & Kilari, D. (2023) · Springer eBooks · doi:10.1007/978-3-031-40901-1_14 · Cited by 1
Ji, X., Yun, Y., Zhu, Z., Wu, T., Ruan, M., Fan, Y., & Zhang, Q. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04266-7
“As c-Myc and Cyclin D1 are key drivers of cell proliferation, this directly links the PPP1R18/ERK/Wnt/β-catenin axis to the proliferative phenotype of ccRCC [56–58].”
The role of the Von Hippel-Lindau tumor suppressor protein in clear cell renal carcinoma.
Rahmy, S. (2014) · Utrecht University Repository (Utrecht University)
The role of stem cells and WNT signalling pathway in renal cell carcinoma
Madlala, S. C. (2020) · Open University of Cape Town (University of Cape Town)
Wang, Q., Xu, J., Xiong, Z., Xu, T., Liu, J., Liu, Y., Chen, J., Shi, J., Shou, Y., Yue, C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16779573
PYGO2 as a tumor marker in low-grade renal cell carcinoma
Golshan, A., Sarli, S., Taghavinia, F., Taghehchian, N., Ghorbani, H., Abbaszadegan, M. R., & Moghbeli, M. (2025) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-025-00707-6
“The levels of Wnt1 and β-catenin expressions were correlated with poor prognosis in RCC patients [26].”
Danielli, L., Rosellini, M., Tassinari, E., Marchetti, A., Mollica, V., Santoni, M., & Massari, F. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2606118
“Alterations include overexpression of ligands (e.g. Wnt1, Wnt10A), downregulation of inhibitors, such as Dickkopf Protein (DKKs), and Secreted Frizzled-Related Protein (sFRPs), and β-catenin nuclear translocation [46,47–50].”
Wang, Q., Xu, J., Xiong, Z., Xu, T., Liu, J., Liu, Y., Chen, J., Shi, J., Shou, Y., Yue, C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16779576
Wang, Q., Xu, J., Xiong, Z., Xu, T., Liu, J., Liu, Y., Chen, J., Shi, J., Shou, Y., Yue, C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16779570
Wang, Q., Xu, J., Xiong, Z., Xu, T., Liu, J., Liu, Y., Chen, J., Shi, J., Shou, Y., Yue, C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16779567
Characterization of wnt signaling in tamoxifen resistant breast cancer stem/progenitor cells
Orue-Etxebarria Iglesias, E. (2018) · Communities in ADDI (Universidad del Pais Vasco)
Hamaidi, I. (2017) · theses.fr (ABES) · doi:10.70675/225493d8z56dfz4991z83dezd7baccef2f11
Caractérisation de nouveaux gènes de prédisposition aux cancers du rein familiaux
Adolphe, F. (2020) · theses.fr (ABES) · doi:10.70675/90d9b0efz660ez4be8z8466z2148c6dc47ad
Metadata
- Authors
- Kruck, S., Eyrich, C., Scharpf, M., Sievert, K.-D., Fend, F., Stenzl, A., & Bedke, J.
- Affiliations
- University of Tübingen (DE)
- Corresponding author
- Bedke, Jens
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2013-05-24
- Volume
- 14
- Issue
- 6
- Pages
- 10944-10957
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC3709711
- OpenAlex
- W2016373982
- Cited by
- 70
- References
- 42
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 6 · 2023: 3 · 2022: 3 · 2021: 10 · 2020: 9 · 2019: 6 · 2018: 4 · 2017: 7 · 2016: 8 · 2015: 2 · 2014: 3 · 2013: 2
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Health Sciences › Medicine › Oncology › Renal and related cancers
- Keywords
- clear cell renal cell carcinoma, Wnt1, β-catenin, Wnt/β-catenin signaling, prognostic factors, overall survival, cancer-specific survival, clinicopathological features, vascular invasion, sarcomatoid differentiation, nuclear beta-catenin expression
- MeSH terms
- Carcinoma, Renal Cell, Cell Membrane, Cytoplasm, Female, Humans, Immunohistochemistry, Kidney, Kidney Neoplasms, Male, Middle Aged, Prognosis, Multivariate Analysis, Proportional Hazards Models, Disease-Free Survival, Wnt1 Protein, beta Catenin, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.